Leman Biotech
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
AI-enabled metabolic cancer immunotherapy company developing next-generation metabolically armored cell therapies to cure solid tumors and hematological cancers.
OncologyImmunology
Technology Platform
Meta 10 metabolic reprogramming platform that reinvigorates exhausted T cells through induction of oxidative phosphorylation, enhanced by AI-driven drug discovery for biomacromolecule optimization.
Opportunities
Expansion into autoimmune diseases demonstrates platform versatility beyond oncology, while the metabolic enhancement approach could unlock solid tumor treatment where current cell therapies have limited efficacy.
Risk Factors
Clinical development risks for novel cell therapies, manufacturing complexities, and intense competition in the CAR-T space from well-funded pharmaceutical companies.
Competitive Landscape
Competes with CAR-T leaders like Novartis, Gilead, and Bristol Myers Squibb, but differentiates through metabolic reprogramming to address T cell exhaustion, particularly for solid tumors where current approaches struggle.